Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2
NCT: NCT03933696 · COMPLETED
NCT IDNCT03933696
StatusCOMPLETED
Start Date2019-01-02
Completion2025-05-31
SponsorIcahn School of Medicine at Mount Sinai (OTHER)
First posted
Last updated
Brief Summary
To test the long term effect of a light treatment on cognition, sleep and metabolism in patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia (ADRD).
Frequently Asked Questions
What is Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2?
Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2 is a clinical trial registered under NCT03933696. Current status: COMPLETED.
What is the status of NCT03933696?
The current status of NCT03933696 (Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2) is: COMPLETED.
When did Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2 start?
Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2 started on 2019-01-02.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.